In February 2023, Charles River Laboratories International Inc., announced the launch of its first enzymes-linked immunoabsorbent assay kit for the detection and quantitation of residual host cell proteins in CHO based bio therapeutics.
This groundbreaking announcement marks as a milestone for Charles River laboratory International, as it expands its portfolio of analytics solutions for the biopharmaceutical industry. The new ELISA kit offers a highly sensitive and specific methods for detecting and quantifying residuals HCPs. These are critical for ensuring the safety and efficacy of bio therapeutic products.
The launch of these ELLSA kit demonstrated Charles River Laboratories International commitment to innovation and quality. By providing a reliable and efficient solution for HCP detection and quantitation. The company is poised to make a positive impact on the biopharmaceutical industry. Bio therapeutic manufacturers can now access a best-in-class analytical tool that enables them to ensure the quality and safety of their products.
With the launch of this new kit by Charles River Laboratories International reinforces its position as a trusted partner for the biopharmaceutical industry. By providing innovative solutions that address the evolving need of manufacturers.
As per the report published by Coherent Market Insights, the global Enzyme Linked Immunosorbent Assay market is set to surge at a CAGR of 5.1% from 2022 to 2030. In 2030, the market is projected to reach at a total of US$ 3,004.3 million from US$ 2,016.1 Million in 2022. Increasing product development activities in the field of Enzyme Linked Immunosorbent Assay will lead to drive demand during the forecast period.
Moreover, rising incidences of infectious disease including dengue, hepatitis, HIV, influenza, malaria, and other infections will lead to boost growth. Growing usage of advanced diagnostic methods such as enzyme-linked immunosorbent assay for screening diseases will lead to fuel growth. Moreover, increasing geriatric population globally and the risk of development of various infections and chronic disorder will lead to fuel growth during the forecast period.
North America is expected to hold dominant position in the global Enzyme Linked Immunosorbent Assay Market by 2030. This is owing to rising incidences rate of chronic diseases, geriatric population, and infectious disease. The development of well-developed healthcare infrastructure and rising penetration of medical devices will fuel growth. Cancer is considered as one of the leading reason of hospitalization in the United States.
However, rising expenditure on research and development by government organization and pharmaceutical companies in terms of disorder and disease. These diseases include diabetes, chronic ailments are some major reason that drive demand in North America market. Asia Pacific is expected to take centerstage in the global market by 2030. This is due to increasing prevalence of chronic diseases.
